Sponsors & Marketing Authorization Holders
The product-owning companies — accountable for the whole lifecycle and for the oversight of every contract manufacturer, lab, CRO, and distributor they rely on.
What this page does not claim
A sector is an organization’s role in the value chain, not a legal category. SPEQ maps the disciplines and standards that role typically operates under; it does not determine which apply to your organization, and a count of decoded standards measures SPEQ’s coverage.
WHAT THIS SECTOR DOES
Sponsors and Marketing Authorization Holders own the product and the marketing authorization. They may outsource manufacturing, testing, research, and distribution, but they remain accountable for the whole lifecycle — for the quality system that ties it together and for the oversight of every contract organization they rely on. The sponsor is the single point of accountability the health authority holds answerable.
REGULATORY LANDSCAPE
The MAH’s duties span the pharmaceutical quality system (ICH Q10), outsourced-activity oversight (EU GMP Chapter 7), pharmacovigilance (EU GVP, with a Pharmacovigilance System Master File and a Qualified Person for Pharmacovigilance), batch certification by a Qualified Person in the EU, and the marketing-application obligations under FDA 21 CFR 314. It is the role that must see across every other sector in this list.
THE OVERSIGHT MODEL
Accountability cannot be outsourced. The sponsor delegates work but retains responsibility: it qualifies and audits its CDMOs, labs, CROs, and distributors; it owns the overarching quality system and the product’s benefit-risk; and it answers to regulators for what its partners do. Effective, risk-based oversight — not just signed Quality Agreements — is what a modern inspection tests.
WHAT QUALITY MEANS HERE
Supplier & partner oversight
Qualifying, auditing, and continuously overseeing every contract manufacturer, lab, CRO, and distributor — the core competency of an outsourced operating model.
The overarching quality system
An ICH Q10 pharmaceutical quality system that governs change, deviation, and CAPA across a network of external partners, not a single site.
Pharmacovigilance & benefit-risk
A functioning safety system (PSMF, QPPV) that maintains the product’s benefit-risk profile across its marketed life.
Lifecycle & maturity
Owning product knowledge, continued process verification, and the quality-management maturity that regulators increasingly assess at the enterprise level.
STANDARDS SPEQ DECODES · 167
Open the full library →WHERE QUALITY FAILS
- Oversight that exists on paper (Quality Agreements) but is not exercised
- A quality system that cannot govern change and CAPA across external partners
- Pharmacovigilance obligations under-resourced relative to the marketed portfolio
- Loss of product/process knowledge when work is fully outsourced
Sponsors & Marketing Authorization Holders: frequently asked questions
Reference answers on what a sponsors & marketing authorization holders does, what governs it, and who is accountable for quality.
What is a Marketing Authorization Holder (MAH)?
A Marketing Authorization Holder — the sponsor — owns the product and the marketing authorization. It may outsource manufacturing, testing, research, and distribution, but it remains accountable for the whole lifecycle: for the quality system that ties it together and for the oversight of every contract organization it relies on. It is the single point of accountability the health authority holds answerable.
What are a sponsor’s core regulatory obligations?
The MAH’s duties span the pharmaceutical quality system (ICH Q10), outsourced-activity oversight (EU GMP Chapter 7), pharmacovigilance (EU GVP, with a Pharmacovigilance System Master File and a Qualified Person for Pharmacovigilance), batch certification by a Qualified Person in the EU, and the marketing-application obligations under FDA 21 CFR 314.
Can a sponsor outsource its accountability?
No. A sponsor can delegate work but not responsibility. It qualifies and audits its CDMOs, labs, CROs, and distributors; it owns the overarching quality system and the product’s benefit-risk; and it answers to regulators for what its partners do. Effective, risk-based oversight — not just signed Quality Agreements — is what a modern inspection tests.